ResMed Inc.
$224.49
▲
1.48%
2026-04-22 10:12:13
www.resmed.com
NYQ: RMD
Explore ResMed Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$32.69 B
Current Price
$224.49
52W High / Low
$293.81 / $202
Stock P/E
22.19
Book Value
$43.39
Dividend Yield
1.06%
ROCE
23.58%
ROE
25.68%
Face Value
—
EPS
$10.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,600
Beta
0.93
Debt / Equity
13.41
Current Ratio
3.06
Quick Ratio
2.53
Forward P/E
18.8
Price / Sales
6.19
Enterprise Value
$32.77 B
EV / EBITDA
16.18
EV / Revenue
6.07
Rating
Buy
Target Price
$296.53
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Anbio Biotechnology | $26.98 | 380.56 | $3.88 B | — | 11.61% | 27.05% | $55.65 / $6.05 | $0.63 |
| 2. | Solventum Corporation | $69.51 | 7.83 | $12.08 B | — | 5.66% | 38.86% | $88.2 / $62.38 | $29.1 |
| 3. | ICU Medical, Inc. | $130.58 | 4,461.76 | $3.27 B | — | 3.08% | 0.04% | $160.29 / $107 | $86.03 |
| 4. | BioLife Solutions, Inc. | $22.19 | — | $1.04 B | — | -4.34% | -3.37% | $29.62 / $17.86 | $7.72 |
| 5. | AptarGroup, Inc. | $125.33 | 21.29 | $8.05 B | 1.47% | 12.5% | 15.1% | $164.28 / $103.23 | $41.56 |
| 6. | Utah Medical Products, Inc. | $70.22 | 20.02 | $225.9 M | 1.77% | 9.51% | 9.54% | $71.81 / $51.26 | $37.43 |
| 7. | Harvard Bioscience, Inc. | $6.99 | — | $30.92 M | — | 0.17% | -1.47% | $9.46 / $2.81 | $3.07 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.42 B | 1.34 B | 1.35 B | 1.29 B | 1.28 B | — |
| Operating Profit | 497.6 M | 462.35 M | 456.57 M | 426.27 M | 417.24 M | — |
| Net Profit | 392.59 M | 348.54 M | 379.7 M | 365.04 M | 344.62 M | — |
| EPS in Rs | 2.69 | 2.39 | 2.61 | 2.51 | 2.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 5.15 B | 4.69 B | 4.22 B | 3.58 B |
| Operating Profit | 1.69 B | 1.38 B | 1.15 B | 1 B |
| Net Profit | 1.4 B | 1.02 B | 897.56 M | 779.44 M |
| EPS in Rs | 9.62 | 7.01 | 6.16 | 5.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.17 B | 6.87 B | 6.75 B | 5.1 B |
| Total Liabilities | 2.21 B | 2.01 B | 2.62 B | 1.74 B |
| Equity | 5.97 B | 4.86 B | 4.13 B | 3.36 B |
| Current Assets | 3.51 B | 2.36 B | 2.37 B | 1.93 B |
| Current Liabilities | 1.02 B | 910.65 M | 758.53 M | 689.3 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.75 B | 1.4 B | 693.3 M | 351.15 M |
| Investing CF | -200.04 M | -269.78 M | -1.16 B | -229.92 M |
| Financing CF | -606.25 M | -1.12 B | 422.87 M | -128.36 M |
| Free CF | 1.65 B | 1.29 B | 559.3 M | 195.11 M |
| Capex | -100.64 M | -114.86 M | -134 M | -156.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 10.95% | 18.02% | — | — |
| Earnings Growth % | 13.75% | 15.15% | — | — |
| Profit Margin % | 21.79% | 21.25% | 21.78% | — |
| Operating Margin % | 29.54% | 27.28% | 28.01% | — |
| Gross Margin % | 56.67% | 55.78% | 56.57% | — |
| EBITDA Margin % | 34.16% | 31.96% | 32.88% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-12 | $0.6 |
| 2025-11-13 | $0.6 |
| 2025-08-14 | $0.6 |
| 2025-05-08 | $0.53 |
| 2025-02-13 | $0.53 |
Stock Splits
No stock split history available.